GleamWall
中文EN

VRTX VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations · Nasdaq · SEC CIK 875320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.5%
TTM net income YoY8.2%
TTM EPS YoY9.4%
Revenue 3-yr CAGR10.3%
Net income 3-yr CAGR4.6%

Margins

Gross margin85.5%
Operating margin33.2%
Net margin30.7%
FCF margin24.7%
EBITDA margin35.1%

Returns

ROE20.8%
ROA13.8%
ROIC (approx.)21.9%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets36.1%
Debt / equity0.22x
Current ratio2.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio1.0%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3.44B$3.33B$2.99B$3.19B$3.08B$2.96B$2.77B$2.91B
Cost of revenue$526.10M$489.20M$392.80M$466.00M$414.80M$407.50M$363.00M$423.40M
Gross profit$2.91B$2.84B$2.59B$2.72B$2.66B$2.56B$2.41B$2.49B
R&D expense$1.32B$993.80M$961.60M$973.70M$977.70M$978.40M$979.70M$998.70M
SG&A expense$844.10M$582.20M$493.70M$487.00M$445.10M$424.60M$396.40M$377.60M
Operating income$712.90M$1.25B$1.14B$1.21B$1.19B$1.15B$630.10M$1.03B
Interest expense$36.00M——$3.30M$3.30M$3.70M$3.00M$2.80M
Pretax income$783.40M$1.39B$1.25B$1.33B$1.30B$1.28B$730.40M$1.14B
Income tax$129.80M$292.00M$221.50M$139.90M$215.90M$250.10M$84.10M$223.50M
Net income$653.60M$1.10B$1.03B$1.19B$1.08B$1.03B$646.30M$913.00M
EBITDA$782.10M$1.30B$1.19B$1.26B$1.24B$1.20B$678.50M$1.07B
EPS (basic)2.584.344.06—4.244.022.52—
EPS (diluted)2.564.314.02—4.203.992.49—
Weighted avg. shares (diluted)255.20M255.20M256.30M—257.60M258.90M259.50M—
Balance sheet
Cash & equivalents$4.98B$6.14B$5.49B$5.08B$4.94B$4.97B$4.67B$4.57B
Short-term investments$1.32B$1.71B$1.75B$1.52B$1.35B$1.41B$1.53B$1.55B
Receivables$2.31B$2.13B$2.00B$2.05B$1.95B$1.89B$1.81B$1.61B
Inventory$2.25B$1.77B$1.77B$1.69B$1.63B$1.50B$1.36B$1.21B
Current assets$11.69B$12.54B$11.73B$11.20B$10.57B$10.43B$10.01B$9.60B
PP&E, net$1.71B$1.67B$1.61B$1.52B$1.43B$1.34B$1.30B$1.23B
Goodwill$2.42B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B
Intangibles$8.52B$412.80M$418.50M$424.20M$429.80M$435.50M$441.20M$825.90M
Total assets$32.74B$27.42B$26.48B$25.64B$24.86B$24.04B$22.88B$22.53B
Current liabilities$5.00B$3.94B$3.88B$3.86B$4.48B$4.14B$3.78B$3.56B
Short-term debt$999.60M——$0————
Long-term debt$3.50B——$0————
Total debt$4.50B——$0————
Total liabilities$11.83B$7.18B$7.12B$6.98B$7.54B$6.86B$6.38B$6.12B
Shareholders' equity$20.91B$20.25B$19.36B$18.67B$17.32B$17.18B$16.50B$16.41B
Net debt-$482.70M——-$5.08B————
Shares outstanding253.52M253.35M254.16M253.99M253.95M256.29M256.97M256.94M
Cash flow statement
Operating cash flow$643.10M$1.13B$1.43B$498.00M$1.24B$1.07B$818.90M$584.60M
Capital expenditure$97.30M$112.20M$133.40M$149.40M$101.80M$145.70M$40.70M$92.60M
Free cash flow$545.80M$1.01B$1.29B$348.60M$1.14B$927.40M$778.20M$492.00M
Investing cash flow-$6.10B-$45.80M-$431.90M-$288.10M-$117.00M-$484.50M-$55.80M-$821.90M
Financing cash flow$4.30B-$426.70M-$538.80M-$77.20M-$1.15B-$349.20M-$680.40M-$391.30M
Depreciation & amortization$69.20M$56.50M$55.90M$55.70M$54.00M$51.70M$48.40M$46.50M
Stock-based compensation$174.40M$170.20M$166.40M$157.60M$194.90M$167.30M$166.10M$167.80M
Share buybacks$126.70M$469.50M$336.90M$128.40M$1.07B$391.80M$426.10M$417.90M

Free plan shows the latest 8 periods; Pro shows all 71 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.